Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction – randomized controlled pilot trial of EPO/AMI-1 study - Ozawa, T; Toba, K; Suzuki, H (Circ J, 2010)
et al.